Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

atorvastatin

Known as: (betaR,deltaR)-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid, (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-pyrrole-1-heptanoic Acid 
A synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which… Expand
National Institutes of Health

Related topics

Related topics

36 relations
Amlodipine / atorvastatinAmlodipine 5 MG / atorvastatin 80 MG Oral Tablet [Caduet]Atorvastatin SodiumAtorvastatin calcium
Expand

Broader (2)

Anticholesteremic AgentsPyrroles

Narrower (6)

CI 981CaduetLipitorLiptruzet
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Adipose Tissue-Derived Omentin-1 Function and Regulation.
Omentin-1, also known as intelectin-1, is a recently identified novel adipocytokine of 313 amino acids, which is expressed in… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
High-dose atorvastatin after stroke or transient ischemic attack.
BACKGROUND Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
BACKGROUND: Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
BACKGROUND Previous trials have demonstrated that lowering low-density lipoprotein (LDL) cholesterol levels below currently… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
background Previous trials have demonstrated that lowering low-density lipoprotein (LDL) cholesterol levels below currently… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
CONTEXT Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
BACKGROUND Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease, but the role of lipid… Expand
  • figure 1
  • table 2
  • figure 2
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which are approved for cholesterol reduction, may… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study : A randomized… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE